SPATA31 subfamily A member 1Genealiases: C9orf36 · C9orf36A · FAM75A1 · FAM75A2 · SPATA31A2
Q-omics provides the consensus-scored SPATA31A1 profile across patient tissues and cancer cell-line models. SPATA31A1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPATA31A1 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SPATA31A1 RNA expression shows 8,636 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where SPATA31A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31A1 survival associations across molecular data types. SPATA31A1 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31A1 RNA expression–survival associations across cancer types. High SPATA31A1 expression shows unfavorable associations in LIHC, BLCA, UCS and UCEC, but favorable associations in UVM and OV. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SPATA31A1 RNA expression.
This table summarizes SPATA31A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31A1 shows higher tumor expression in HNSC, BRCA, LUSC, PRAD and STAD. The HNSC box plot shows higher SPATA31A1 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .001).
This table shows molecular features associated with SPATA31A1 in patient tissues and cancer cell lines. In patient samples, SPATA31A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA31A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
